Along with the augmentation of the vasodilatatory natriuretic peptides in conjunction with the renin–angiotensin system pharmacological blockade, the drug has been shown to exert neuroadrenergic inhibitory effects, as documented by the reduction (about 30% in magnitude) in the sympathetic nerve traffic values after a two-month treatment in CHF patients with reduced ejection fraction [36]. Here, REN is linked to congestive heart failure.